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 Ischemic preconditioning is an innate 
tissue adaptation induced by ischemia or 
toxic insult that confers both local 
and remote organ protection against 
subsequent exposure to the same or other 
injury. Local ischemic preconditioning was 
fi rst observed in dogs as the limitation of 
myocardial infarct size produced by a series 
of brief (4 × 5  min) circumfl ex artery occlu-
sions and reperfusions before a more 
sustained occlusion of the same artery. 1 
Later studies identifi ed the existence of 
remote ischemic preconditioning (RIPC), 
where transient ischemia of many organs 
and tissues, including heart, kidney, small 
bowel, liver, and skeletal muscle, induced 
systemic multiorgan protection against 
subsequent extended ischemia – reper-
fusion injury. 2,3 Ischemic preconditioning 
is highly conserved across species. 2 RIPC 
suggests the involvement of humoral medi-
ators, and many experiments demonstrate 
that protection is dialyzable, transferable, 
and receptor-mediated. 2,3 Th e observation 
that upper- or lower-limb ischemia 
induced by infl ation of a blood pressure 
cuff  provided myocardial protection in the 
absence of known adverse risks, and that 
protection could occur aft er initiation of 
injury (postconditioning), off ers a tantaliz-
ing, cheap, and easily applicable strategy 
for the prevention of acute kidney injury 
(AKI) in high-risk patients, provided that 
real clinical benefi ts are reproducible. 
Classically, local ischemic precondition-
ing induces immediate (early) protection, 
which wanes aft er a few hours. Early protec-
tion is followed by a delayed phase of pro-
tection that appears about 12 – 24  h aft er the 
inducing stimulus. Delayed protection is 
weaker but usually persists for days. 2,3 RIPC 
induces similar early and late protection, 
and both types of preconditioning occur 
largely through modulation of the response 
to reperfusion. Nevertheless, there are 
mechanistic diff erences between local and 
remote preconditioning, 2 and the details of 
signal transduction and eff ectiveness vary 
among species and the type of stimulus. 
Various humoral factors, including adeno-
sine, bradykinin, and cannabinoids, may be 
involved, and subcellular modulators such 
as nuclear factor- κ B and nitric oxide appear 
to be involved ( Figure 1 ). 2 – 4 Interestingly, 
preconditioning appears to require intact 
innervation of the preconditioning organ 
but not the target organ. Similarly, early and 
late ischemic preconditioning diff er in the 
relative importance of mediators, signal 
transduction pathways, and end eff ectors. 
Th e fi nal common pathway appears to be a 
cascade of intracellular kinases with 
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 subsequent opening of adenosine triphos-
phate-sensitive potassium channels and 
closure of the mitochondrial permeability 
pore ( Figure 1 ). 5 RIPC also induces sys-
temic anti-infl ammatory eff ects and reduces 
endothelial dysfunction, which may con-
tribute to multiorgan protection. 2 
 It has been known for almost a century 
that prior injury protects the kidney against 
subsequent injury, 5 with recent studies 
highlighting modulation of infl ammation 
in ischemic renal preconditioning. 6 Never-
theless, most studies of RIPC have focused 
on the protection of the organs undergoing 
direct ischemia – reperfusion injury, such as 
the heart and lungs in cardiopulmonary 
bypass surgery, and kidneys in aortic 
surgery. 7 However, the systemic multiorgan 
protection offered by RIPC, including 
induction of anti-infl ammatory and anti-
apoptotic gene profi les, suggests potential 
benefi t in prevention of AKI during cardi-
opulmonary bypass. Indeed, RIPC has 
shown renal-protective eff ects in major vas-
cular surgery or interventions without 
direct interruption of perfusion to the kid-
neys. 7 Nevertheless, renal protection has 
not been universally observed, 8 although 
problems arise when the assessment of renal 
dysfunction is an add-on to studies focused 
on cardiac function. For example, Rahman 
 et al. 8 assessed renal function only 4 days 
aft er surgery, which was too late to detect 
mild to moderate renal dysfunction. 
 A number of studies have now addressed 
renal protection as a primary outcome fol-
lowing RIPC. Firstly, Venugopal  et al. 9 per-
formed a secondary analysis of renal 
outcomes of two randomized placebo-
controlled trials of RIPC for myocardial 
protection, which used three 5-min cycles 
of arm ischemia followed by reperfusion in 
78 patients undergoing cardiac surgery. 
Th is retrospective analysis showed a reduc-
tion in the incidence of stages 1, 2, and 3 of 
AKI by the AKI Network (AKIN) criteria 
from 25, 0, and 0 % in the control to 3, 8, 
and 0 % in the RIPC group. Secondly, a pro-
spective randomized double-blind con-
t rolled trial of RIPC by Choi  et al. 10 used 
three 10-min cycles of lower-limb (thigh) 
ischemia and reperfusion in 76 patients 
undergoing complex valvular cardiac sur-
gery. The primary outcomes were AKI 
incidence (AKIN defi nition) and changes 
in plasma cystatin C at 24 and 48  h aft er 
bypass and in the renal injury biomarker 
plasma neutrophil gelatinase-associated 
lipocalin (NGAL) at 24  h after bypass. 
Th ere were no diff erences in incidence of 
AKI (12 / 38 in control and 14 / 38 in RIPC 
group) or in the concentrations of renal 
injury biomarkers between the two groups, 
although there was a decrease in the crea-
tine kinase MB fraction and in the length 
of intensive care unit stay in the RIPC 
group, supporting cardiac benefi t. 
 Zimmerman  et al. 11 (this issue) report a 
randomized single-blind controlled pilot 
study of RIPC that used three 5-min cycles of 
lower-limb (thigh) ischemia and reperfusion 
in 120 patients undergoing cardio pulmonary 
bypass surgery. Th e primary outcome was the 
incidence of AKI (AKIN defi nition), and the 
secondary outcomes included change in 
plasma NGAL 3  h aft er bypass. Th ere was an 
absolute risk reduction in AKI of 0.27 (95 % 
confi dence interval, 0.10 – 0.42) with a change 
in incidence from 28 / 59 (47 % ) in the control 
to 12 / 59 (20 % ) in the RIPC group ( P  =  0.004). 
 Post hoc analysis of the latter study also 
showed a reduction in both stage 1 and stage 
2 grades of injury versus controls (there were 
no stage 3 patients in either group). Th ere was 
also a reduction in the incidence of AKI sus-
tained for at least 2 days in the RIPC group 
( P  =  0.04). As with the previous study, 10 there 
was no diff erence in the change in plasma 
NGAL levels between the two groups. 
 What conclusions are we to draw from 
the two prospective studies? Firstly, both 
should be considered pilot studies, as they 
are underpowered to assess RIPC as a ther-
apeutic intervention. Th e overall incidence 
of AKI, by the same defi nition of AKI, was 
greater in control subjects in the study by 
Zimmerman  et al. 11 (47 % ) than the overall 
incidence in the study by Choi  et al. 10 (37 % ), 
suggesting differences in the propensity 
scores for AKI, although the control and 
RIPC groups were well matched within each 
study. Th is refl ects the exclusion of patients 
with preexisting renal dysfunction by Choi 
 et al. 10 Th at study observed evidence for 
myocardial protection and reduced length 
of intensive care unit stay as tangible benefi t 
in the RIPC group. Surprisingly, length of 
intensive care unit stay appeared the same 
in the control and RIPC groups in the study 
by Zimmerman  et al. 11 despite the massive 
reduction in AKI incidence in the RIPC 
group. It is not clear whether the detection 
of stages 1 and 2 AKI was a factor in guiding 
clinical management in that study despite a 
growing literature suggesting that even small 
increases in creatinine are associated with 
adverse short- and long-term outcomes. As 
change in cardiac biomarkers was not 
reported, it is unclear whether there was 
cardiac protection from RIPC in the study 
by Zimmerman  et al. 11  No patients requir-
ing dialysis (AKIN stage 3) were reported in 
either study, so neither off ers insight into the 
eff ect of RIPC on severe AKI. 
 Absence of severe AKI may also explain 
why plasma NGAL did not detect AKI 
in either study. With less severe AKI in the 
low-risk cohort in the study by Choi  et al. , 10 
any increase in this relatively short-lived 
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 Figure 1  |  Remote ischemic preconditioning. Schematic illustration of pathways potentially involved in remote ischemic preconditioning in animal models 
and humans. Organs in which protection has been observed experimentally include the brain, heart, kidney, liver, and lung. Cycles of ischemia – reperfusion have 
used upper- and lower-limb ischemia as well as other vascular beds, including the common iliac artery. ATP, adenosine triphosphate; NF- κ B, nuclear factor- κ B. 
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AKI biomarker would have nor ma lized 
within 24  h when sampling was per formed. 
An alternative explanation is that the 
performance of all urinary biomark ers, 
including NGAL, is reduced and delayed in 
patients with chronic kidney disease 
(CKD). 12 Our analysis of plasma NGAL 
data in the EARLYARF study 12,13 showed a 
similar dependence of performance on base-
line renal function and duration of injury to 
the urinary markers (unpublished data). 
Thus, although Zimmerman  et al. 11 
collected NGAL data at the potentially 
optimal time of 3  h aft er bypass, that time is 
not optimal for patients with CKD! Th us 
inclusion of patients with baseline CKD has 
the eff ect of creating a more realistic but also 
more heterogeneous population from a 
biomarker perspective. Stratifying for base-
line renal function would require a much 
larger number of patients. For these reasons, 
the NGAL results were unhelpful in both 
studies in detecting renal injury independ-
ently of change in serum creatinine. 
 Overall, the results of RIPC in these two 
studies 10,11 appear consistent with the pro-
pensity for development of AKI in the 
patient cohorts studied. The lower the 
expected incidence of AKI, the larger the 
study required to assess renal protection. 
CKD is a well-known risk factor for AKI 
and is present in approximately 30 % of 
cases. We should therefore be encouraged 
by the outcome in the more realistic popu-
lation in the Zimmerman  et al. pilot study 
in patients reported here, 11 in which 16 % 
had underlying CKD (estimated glomeru-
lar filtration ate   <  60  ml / min / 1.73  m 2 ). 
Nevertheless, the dose and type of ischemic 
preconditioning needed are not yet estab-
lished, and the eff ects of age, drugs, and 
comorbidity on the response to RIPC await 
validation in much larger multicenter stud-
ies. It remains to be seen whether renal 
protection is independent of improving 
myocardial function with RIPC. 
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 Immunosuppressive 
treatment of focal segmental 
glomerulosclerosis: lessons from 
a randomized controlled trial 
 Jeroen K.J.  Deegens 1 and  Jack F.M.  Wetzels 1 
 Patients with steroid-resistant focal segmental glomerulosclerosis 
(FSGS) may benefit from treatment with calcineurin inhibitors. 
A National Institutes of Health – funded FSGS multicenter study has 
suggested that a combination of mycophenolate mofetil and oral 
dexamethasone pulses was equivalent to cyclosporine. However, since 
the study was underpowered, one cannot draw firm conclusions from 
this study. The FSGS trial underscores that FSGS is not one disease and 
that better predictors of outcome and response to therapy are needed. 
 Kidney International (2011)  80, 798 – 801.  doi: 10.1038/ki.2011.191 
underlying cause). 1 In recent years, many 
new causes of FSGS have been identifi ed. 
Th e prognosis of FSGS is predicted by the 
severity and persistence of proteinuria, with 
60 % of patients with persistent nephrotic-
range proteinuria progressing to end-stage 
renal disease within 5 – 10 years. 2 Achieve-
ment of a remission, whether spontaneous 
or induced by immunosuppressive therapy, 
is associated with a good outcome. 1 
 Although there is no evidence from ran-
domized controlled trials, corticosteroids 
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 Focal segmental glomerulosclerosis (FSGS) 
is one of the most common patterns of 
glomerular injury and an important cause 
of end-stage renal disease in both adults 
and children. FSGS can be idiopathic 
(with unknown cause) or secondary (with 
